-
Lunch Break
Done
-
Oral Session III A
Mariana FiadeiroDone
-
Enterprise Plenary Session III
Sofia Venceslau (Ph.D.)Done
-
Flash Session II (C)
Ana F. PereiraDone
-
Oral Session I A
Cristiana MateusDone
-
Oral Session IV B
Rita Lima-SousaDone
-
Oral Session I B
Diana PereiraDone
-
Poster Session II (w/ Refreshment Break)
Done
-
Flash Session III (D)
Joana FerreiraDone
-
Oral Session III B
Ana R. CostaDone
Hot Topic Session: "New biomolecules: Challenges in the development and clinical translation" will be on February 14th, where the point of view of a well-established pharmaceutical company (Angelini Pharma) and a biotechnology spin-off (Immunethep) will be discussed.
ANGELINI Pharma Portugal has a wide range of products, being one of the most comprehensive pharmaceutical laboratories in the market, assisting in areas such as Diseases of the Central Nervous System, Mental Disorders, Inflammation, and Anti Flu. Carlos Neto currently works in the Medical Affairs department at Angelini Pharma and will be representing the company in this Hot Topic session of the HSR Congress.
IMMUNETHEP is a biotechnology company created in 2013 as a spin-off being established in the Biocant Park. Focusing on the development of immunotherapies for infectious diseases, IMMUNETHEP is actually the first Portuguese company to develop a vaccine against Covid-19 (pre-clinical trials) and will soon be the first company in the world with a multibacterial vaccine under clinical trials. Pedro Madureira (PhD) is co-founder and CSO at Immunethep and will be representing the company at this Hot Topic session of the HSR congress.
